AZD6482 Clinical Trials

Size	Price	Qty
5mg	USD 170
50mg	USD 970

Clinical Trials

AstraZeneca has sponsored multiple completed Phase 1 clinical trials to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD6482. These early-stage human studies evaluated the compound's antiplatelet effects, including direct comparisons of bleeding time parameters against clopidogrel. Collectively, these completed trials provide essential clinical evidence supporting the therapeutic evaluation of AZD6482 for antiplatelet applications.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00688714	COMPLETED	Antiplatelet Effect	AstraZeneca	2008-01	PHASE1
NCT00853450	COMPLETED	Antiplatelet Effect	AstraZeneca	2009-02	PHASE1

(data from https://clinicaltrials.gov, updated on 2008-06-03)

Check the AZD6482 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

AZD6482 selectively binds to phosphoinositide 3-kinase beta (PI3Kβ) to inhibit downstream lipid kinase activity, thereby suppressing intracellular signaling pathways required for platelet activation and aggregation. Consequently, this targeted cellular inhibition prevents pathological thrombus formation while maintaining normal hemostasis, providing the mechanistic rationale for its clinical evaluation in establishing an optimal antiplatelet effect.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).